Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Multiple Myeloma
Real-World Analysis of Treatment Patterns and Outcomes in Patients with MM by Cytogenetic Risk
Read More
Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1/2 Results from MonumenTAL-1
Read More
Systematic Review and Meta-Analysis Comparing Whole-Body MRI and FDG PET/CT in Evaluating Treatment Response in Multiple Myeloma
Read More
Isatuximab plus Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: ICARIA-MM Final OS Analysis
Read More
Daratumumab plus Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: Long-Term Outcomes from MAIA
Read More
Patient and Caregiver Preferences for RRMM Treatment Should Be Considered Using Shared Decision-Making
Read More
Ciltacabtagene Autoleucel Shows Promising Results in Patients with Multiple Myeloma Who Have Experienced Early Clinical Relapse
Read More
Updated Results from IKEMA Demonstrate a Median PFS of Nearly 3 Years with Isa-Kd
Read More
Daratumumab + Cyclophosphamide, Bortezomib, and Dexamethasone Induction Followed by Daratumumab Maintenance Achieved Durable Responses in Patients with RRMM and NDMM
Read More
Addition of ASCT to Triplet Induction and Lenalidomide Maintenance to Progression: Results from the DETERMINATION Trial
Read More
1
2
3
4
5
Page 2 of 10
Results 11 - 20 of 98